View in EDS HTML Full Text PDF Full Text

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.

Saved in:
Bibliographic Details
Title: Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Authors: Torka P; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Akhtar OS; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Reddy NM; Vanderbilt University Medical Center, Nashville, Tennessee., Baysal BE; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Kader A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Groman A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Nichols J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Mavis C; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Tario JD; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Block AW; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Sait SNJ; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Ghione P; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Sundaram S; Icahn School of Medicine at Mount Sinai, New York, New York., Przespolewski ER; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Mohr A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Lund I; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Kostrewa J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., McWhite K; Roswell Park Comprehensive Cancer Center, Buffalo, New York., DeMarco J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Johnson M; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Darrall A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Thomas-Talley RN; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Wallace PK; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Neppalli V; University of Manitoba, Winnipeg, Manitoba, Canada., Hutson A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Hernandez-Ilizaliturri FJ; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Source: Cancer [Cancer] 2022 Apr 15; Vol. 128 (8), pp. 1595-1604. Date of Electronic Publication: 2022 Feb 14.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35157306
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Torka+P%22">Torka P</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Akhtar+OS%22">Akhtar OS</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Reddy+NM%22">Reddy NM</searchLink>; Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Baysal+BE%22">Baysal BE</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Kader+A%22">Kader A</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Groman+A%22">Groman A</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Nichols+J%22">Nichols J</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Mavis+C%22">Mavis C</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Tario+JD%22">Tario JD</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Block+AW%22">Block AW</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Sait+SNJ%22">Sait SNJ</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Ghione+P%22">Ghione P</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Sundaram+S%22">Sundaram S</searchLink>; Icahn School of Medicine at Mount Sinai, New York, New York.<br /><searchLink fieldCode="AU" term="%22Przespolewski+ER%22">Przespolewski ER</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Mohr+A%22">Mohr A</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Lund+I%22">Lund I</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Kostrewa+J%22">Kostrewa J</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22McWhite+K%22">McWhite K</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22DeMarco+J%22">DeMarco J</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Johnson+M%22">Johnson M</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Darrall+A%22">Darrall A</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Thomas-Talley+RN%22">Thomas-Talley RN</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Wallace+PK%22">Wallace PK</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Neppalli+V%22">Neppalli V</searchLink>; University of Manitoba, Winnipeg, Manitoba, Canada.<br /><searchLink fieldCode="AU" term="%22Hutson+A%22">Hutson A</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.<br /><searchLink fieldCode="AU" term="%22Hernandez-Ilizaliturri+FJ%22">Hernandez-Ilizaliturri FJ</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2022 Apr 15; Vol. 128 (8), pp. 1595-1604. <i>Date of Electronic Publication: </i>2022 Feb 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35157306
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.34106
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1595
    Titles:
      – TitleFull: Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Torka P
      – PersonEntity:
          Name:
            NameFull: Akhtar OS
      – PersonEntity:
          Name:
            NameFull: Reddy NM
      – PersonEntity:
          Name:
            NameFull: Baysal BE
      – PersonEntity:
          Name:
            NameFull: Kader A
      – PersonEntity:
          Name:
            NameFull: Groman A
      – PersonEntity:
          Name:
            NameFull: Nichols J
      – PersonEntity:
          Name:
            NameFull: Mavis C
      – PersonEntity:
          Name:
            NameFull: Tario JD
      – PersonEntity:
          Name:
            NameFull: Block AW
      – PersonEntity:
          Name:
            NameFull: Sait SNJ
      – PersonEntity:
          Name:
            NameFull: Ghione P
      – PersonEntity:
          Name:
            NameFull: Sundaram S
      – PersonEntity:
          Name:
            NameFull: Przespolewski ER
      – PersonEntity:
          Name:
            NameFull: Mohr A
      – PersonEntity:
          Name:
            NameFull: Lund I
      – PersonEntity:
          Name:
            NameFull: Kostrewa J
      – PersonEntity:
          Name:
            NameFull: McWhite K
      – PersonEntity:
          Name:
            NameFull: DeMarco J
      – PersonEntity:
          Name:
            NameFull: Johnson M
      – PersonEntity:
          Name:
            NameFull: Darrall A
      – PersonEntity:
          Name:
            NameFull: Thomas-Talley RN
      – PersonEntity:
          Name:
            NameFull: Wallace PK
      – PersonEntity:
          Name:
            NameFull: Neppalli V
      – PersonEntity:
          Name:
            NameFull: Hutson A
      – PersonEntity:
          Name:
            NameFull: Hernandez-Ilizaliturri FJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 04
              Text: 2022 Apr 15
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 128
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1